ACET
Price
$0.71
Change
-$0.01 (-1.39%)
Updated
Apr 3, 02:23 PM (EDT)
Capitalization
59.86M
47 days until earnings call
SUPN
Price
$32.82
Change
+$1.14 (+3.60%)
Updated
Apr 2 closing price
Capitalization
1.84B
40 days until earnings call
Ad is loading...

ACET vs SUPN

Header iconACET vs SUPN Comparison
Open Charts ACET vs SUPNBanner chart's image
Adicet Bio
Price$0.71
Change-$0.01 (-1.39%)
Volume$300
Capitalization59.86M
Supernus Pharmaceuticals
Price$32.82
Change+$1.14 (+3.60%)
Volume$373.15K
Capitalization1.84B
ACET vs SUPN Comparison Chart
Loading...
ACET
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SUPN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACET vs. SUPN commentary
Apr 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACET is a Hold and SUPN is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 03, 2025
Stock price -- (ACET: $0.72 vs. SUPN: $32.82)
Brand notoriety: ACET and SUPN are both not notable
ACET represents the Biotechnology, while SUPN is part of the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: ACET: 47% vs. SUPN: 59%
Market capitalization -- ACET: $59.86M vs. SUPN: $1.84B
ACET [@Biotechnology] is valued at $59.86M. SUPN’s [@Pharmaceuticals: Other] market capitalization is $1.84B. The market cap for tickers in the [@Biotechnology] industry ranges from $308.32B to $0. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACET’s FA Score shows that 1 FA rating(s) are green whileSUPN’s FA Score has 0 green FA rating(s).

  • ACET’s FA Score: 1 green, 4 red.
  • SUPN’s FA Score: 0 green, 5 red.
According to our system of comparison, ACET is a better buy in the long-term than SUPN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACET’s TA Score shows that 2 TA indicator(s) are bullish while SUPN’s TA Score has 4 bullish TA indicator(s).

  • ACET’s TA Score: 2 bullish, 7 bearish.
  • SUPN’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, SUPN is a better buy in the short-term than ACET.

Price Growth

ACET (@Biotechnology) experienced а -19.22% price change this week, while SUPN (@Pharmaceuticals: Other) price change was +1.52% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.54%. For the same industry, the average monthly price growth was -10.57%, and the average quarterly price growth was -14.69%.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -2.35%. For the same industry, the average monthly price growth was +65.59%, and the average quarterly price growth was -10.19%.

Reported Earning Dates

ACET is expected to report earnings on May 20, 2025.

SUPN is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (-8.54% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

@Pharmaceuticals: Other (-2.35% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SUPN($1.84B) has a higher market cap than ACET($59.9M). SUPN YTD gains are higher at: -9.237 vs. ACET (-24.740). SUPN has higher annual earnings (EBITDA): 90M vs. ACET (-110.65M). SUPN has more cash in the bank: 255M vs. ACET (176M). ACET has less debt than SUPN: ACET (17.2M) vs SUPN (41.5M). SUPN has higher revenues than ACET: SUPN (608M) vs ACET (0).
ACETSUPNACET / SUPN
Capitalization59.9M1.84B3%
EBITDA-110.65M90M-123%
Gain YTD-24.740-9.237268%
P/E RatioN/A1677.00-
Revenue0608M-
Total Cash176M255M69%
Total Debt17.2M41.5M41%
FUNDAMENTALS RATINGS
ACET vs SUPN: Fundamental Ratings
ACET
SUPN
OUTLOOK RATING
1..100
647
VALUATION
overvalued / fair valued / undervalued
1..100
36
Fair valued
71
Overvalued
PROFIT vs RISK RATING
1..100
10040
SMR RATING
1..100
9878
PRICE GROWTH RATING
1..100
9072
P/E GROWTH RATING
1..100
15100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ACET's Valuation (36) in the Medical Distributors industry is somewhat better than the same rating for SUPN (71) in the Pharmaceuticals Other industry. This means that ACET’s stock grew somewhat faster than SUPN’s over the last 12 months.

SUPN's Profit vs Risk Rating (40) in the Pharmaceuticals Other industry is somewhat better than the same rating for ACET (100) in the Medical Distributors industry. This means that SUPN’s stock grew somewhat faster than ACET’s over the last 12 months.

SUPN's SMR Rating (78) in the Pharmaceuticals Other industry is in the same range as ACET (98) in the Medical Distributors industry. This means that SUPN’s stock grew similarly to ACET’s over the last 12 months.

SUPN's Price Growth Rating (72) in the Pharmaceuticals Other industry is in the same range as ACET (90) in the Medical Distributors industry. This means that SUPN’s stock grew similarly to ACET’s over the last 12 months.

ACET's P/E Growth Rating (15) in the Medical Distributors industry is significantly better than the same rating for SUPN (100) in the Pharmaceuticals Other industry. This means that ACET’s stock grew significantly faster than SUPN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACETSUPN
RSI
ODDS (%)
N/A
Bullish Trend 1 day ago
82%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
87%
Bearish Trend 1 day ago
66%
Momentum
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
81%
MACD
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
72%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
71%
Advances
ODDS (%)
Bullish Trend 11 days ago
83%
Bullish Trend 10 days ago
74%
Declines
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 22 days ago
66%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
78%
N/A
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
62%
View a ticker or compare two or three
Ad is loading...
ACET
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SUPN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JORCX16.670.11
+0.66%
Janus Henderson Global Select C
REMKX18.68N/A
N/A
Victory Sophus Emerging Markets R
JIUCX15.20N/A
N/A
JPMorgan Developed International Value C
AHSAX18.60N/A
N/A
Alger Health Sciences A
JUEPX23.32N/A
N/A
JPMorgan US Equity R3

ACET and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACET has been loosely correlated with ARWR. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ACET jumps, then ARWR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACET
1D Price
Change %
ACET100%
-1.50%
ARWR - ACET
42%
Loosely correlated
+3.97%
OGI - ACET
41%
Loosely correlated
-0.96%
DVAX - ACET
39%
Loosely correlated
+1.26%
CCCC - ACET
37%
Loosely correlated
+5.92%
CABA - ACET
36%
Loosely correlated
+5.98%
More

SUPN and

Correlation & Price change

A.I.dvisor tells us that SUPN and DVAX have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SUPN and DVAX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SUPN
1D Price
Change %
SUPN100%
+3.60%
DVAX - SUPN
30%
Poorly correlated
+1.26%
SNDL - SUPN
27%
Poorly correlated
N/A
ACET - SUPN
27%
Poorly correlated
-1.50%
ESPR - SUPN
26%
Poorly correlated
-1.42%
MKKGY - SUPN
24%
Poorly correlated
+0.48%
More